Abstract Coronary atherosclerosis is a complex heritable trait with an enigmatic genetic etiology. Genome-wide association studies (GWAS) have successfully led to identification of over 100 different loci for susceptibility to coronary atherosclerosis. Most identified single nucleotide polymorphisms (SNP)s and genes have not been previously implicated in the pathogenesis of atherosclerosis and hence, have modest biological plausibility. The novel discoveries, however, might provide the opportunity for identification of new pathways and consequently novel preventive and therapeutic targets. A notable outcome of GWAS is relatively modest effect sizes of the associated SNPs. Collectively, the identified SNPs account for a relatively small fraction of heritability of coronary atherosclerosis, which raises the question of "missing heritability". Because GWAS test the common disease-comment variant hypothesis, a plausible explanation might be the presence of uncommon and rare variants in the genome that are untested in GWAS but that might exert large effect sizes on the risk of atherosclerosis. The latter, however, remains an empiric question pending validation through experimentation. Alternative mechanisms, such as transgenerational epigenetics including microRNAs, might in part account for the heritability of coronary atherosclerosis. Collectively, the recent findings are indicative of the etiological complexity of coronary atherosclerosis. Hence, it is expected that genetic etiology of coronary atherosclerosis will remain enigmatic in the foreseeable future.
Introduction
Atherosclerosis, whether involving coronary or other vascular systems, is a complex phenotype and like any other complex trait, is in part genetically programmed. The initial evidence for a genetic etiology of atherosclerosis was based on the demonstration of familial aggregation and heritability estimates [1, 2] , which stimulated the search for identifying the risk alleles. The candidate gene approach through case-control allelic association studies has implicated a number of DNA sequence variants (DSVs) in susceptibility to coronary atherosclerosis and myocardial infarction. However, the results have been inconsistent and subject to a high rate of spurious association. The advent of genome-wide association studies (GWAS) ushered in an unbiased genomewide approach that raised considerable hope in identifying the genetic determinants of susceptibility to atherosclerosis. GWAS has become the state-of-the-art approach for genetic studies of complex disease and has been applied almost to all complex phenotypes successfully to identify the risk alleles. As of February 23, 2012, 1179 GWAS studies reporting 5876 phenotype-associated single nucleotide polymorphisms (SNPs) have been listed in the catalog of published GWAS (http://www.genome.gov/gwastudies/). Likewise, 16 GWAS studies of "coronary heart disease", 4 of "myocardial infarction" and 2 of "coronary artery calcification" have been catalogued (www.genome.gov/gwastudies/ ). GWAS of "coronary heart disease" collectively have led to identification of 80 susceptibility genes (clusters) and about 40 intergenic regions. Despite the plethora of GWAS, it has become evident that the results of GWAS are unlikely to fully explain the genetic basis of coronary atherosclerosis and explain only a small fraction of its heritability. Thus, it appears that a significant portion of heritability of coronary atherosclerosis remains to be discovered. In this review, we provide an overview of the results of GWAS of "coronary heart disease" and discuss other genetic and genomic factors that might account for the "missing heritability" of coronary atherosclerosis.
Genetic Etiology of Coronary Atherosclerosis Identified by GWAS
GWAS is an array-based genotyping approach designed to type the study population-typically cases and controls-for a very large number of known common variants, as defined by a minor allele frequency of >0.05) [3•] . Thus, GWAS tests the common disease-common variant hypothesis (CD-CV). In less than a decade since its initial introduction, over 100 loci have been associated with "coronary heart disease", the term commonly used in GWAS of coronary atherosclerosis, even though it likely entails multiple related but partially independent phenotypes and is not sufficiently specific. As would be expected and to some extent gratifying, the findings show association of SNPs in several genes coding for the established risk factors and "coronary heart disease" (Table 1) . However, the majority of the genes identified through the GWAS have not been previously implicated in the pathogenesis of atherosclerosis, and hence, in this aspects are novel genes ( Table 2 ). Identification of the novel genes is indeed the strength of the GWAS, as it is devoid of a priori hypothesis for the candidacy of a gene and is rather an unbiased survey of the genome. In addition, a high threshold for the statistical significance is often adopted in order to account for the opportunity for multiple hypothesis testing and reduce the chance of spurious associations. Moreover, the GWAS findings are typically replicated in independent study populations to strengthen the findings, as otherwise considered provisional. Thus, considering these cautionary steps built into the design of GWAS, all novel genes identified through this approach have the potential to shed new light into the molecular mechanisms of atherosclerosis.
The list of novel genes for atherosclerosis identified through GWAS is intriguing (Table 2) . Most if not all have met a priori set criteria for statistical significance and most have been replicated in independent populations. Several genes, such as CXC12 [4] , are biologically plausible candidates that might regulate pathways implicated in atherosclerosis. The majority, however, suffer from low biological plausibility for influencing susceptibility to coronary atherosclerosis. Nevertheless, biological plausibility is based on a prior knowledge and hence, a modest biological plausibility does not necessarily negate a potential causal role in atherosclerosis. These novel findings raise several possibilities, among them the possibility that a large number of pathways responsible for coronary atherosclerosis remain to be discovered. It is, however, perplexing to fathom SNPs in a gene that has been implicated in cancer or myopathies predisposes to coronary atherosclerosis, knowing that such phenotypes are not known to be associated with atherosclerosis. Nevertheless, phenotypic plasticity is not an uncommon feature of genes as many might exhibit remarkable phenotypic plasticity, as best exemplified by LMNA, which encodes nuclear envelope protein lamin A/ C. Mutations in LMNA are known to be responsible for over a dozen distinct phenotypes [5] . A plausible alternative possibility is linkage disequilibrium (LD) between alleles identified through GWAS and the true risk alleles. The size of LD varies in different genomic regions and in different ethnic backgrounds [6] . It typically encompasses blocks of 10 to 25 kbp in size but could extend into much larger blocks and on occasion involve several million base pairs containing multiple genes [6] [7] [8] . Thus, it is likely that the SNPs identified through GWAS are not the true susceptibility alleles but in LD with them. One also has to consider the possibility of spurious association in same cases, in spite of robust statistical association and even replication. Collectively, the results of GWAS provide the initial clues necessary for further refined genetic studies to identify the true risk alleles.
A notable feature common to genetic studies of complex traits by the GWAS approach is the relatively modest effect sizes of the phenotype-associated alleles. This is best illustrated for quantitative traits such as plasma high-density lipoprotein cholesterol (HDL-C) level or systemic arterial blood pressure. SNPs identified through GWAS shift plasma HDL-C level by 1 mg/dL or less and those associated with hypertension shift systolic or diastolic blood pressure by 1 mmHg or less [9, 10, 11•] . Likewise, for phenotypes such as "coronary heart disease" SNPs identified through GWAS impart modest risk, typically a relative risk in the range of 1.1 to 1.2 [12] . The relatively modest effect sizes of the alleles on complex phenotypes mitigate the clinical impact of identification of the susceptibility alleles for genetic-based risk stratification or prognostication and with some exceptions, in individualization of pharmacological and non-pharmacological therapy.
The main, and probably the only, strength of the results of GWAS is in providing novel mechanistic insights into the pathogenesis of the complex traits. Two notable loci discovered through GWAS are the 9p21 and 1p13 loci, which are probably the best-characterized GWAS loci for coronary heart disease, other than the lipid-related genes. The 9p21 locus is a genedesert locus that has been linked to coronary atherosclerosis in multiple studies [13] [14] [15] . The locus contains CDKN2B-AS1, also known as ANRIL, which codes for a long non-coding RNA (lnRNA). Immediately adjacent to the refined locus are CDKN2A and CDKN2B, which code for cell cycle regulators and tumor suppressor proteins CDKN2A and CDKN2B [16] . Reduced expression levels of Cdkn2a and Cdkn2b are associated with enhanced proliferation and reduced senescence of smooth muscle cells [17•] . The region also contains a number of enhancers including an enhancer for STAT1, which is a signal transducer for interferons and cytokines [18••] . The 9p21 risk alleles disrupt the binding site for STAT1, leading to enhanced expression of CDKN2B-AS1 in response to inflammation [18••] . Thus, it is plausible that the 9p21 locus imparts its effects on susceptibility to atherosclerosis through an enhanced expression of CDKN2B-AS1 to inflammation, suppression of expression of CDKN2B and ensuing increased proliferation of smooth muscle cells in the vessel wall [17•, 18••] .
The precise mechanism(s) by which the 1p13 locus influences the risk of coronary atherosclerosis is uncertain but seems to relate to the LDL-C uptake in the liver, as discussed by Strong and Rader in this issue of the Current Atherosclerosis Reports. The minor allele of the risk SNP creates a C/EBP-α binding site on the SORT1 promoter, which leads to increased expression level of SORT1 [19••] . Forced expression of Sort1 is associated with reduced plasma LDL-C levels. In contrast, suppression of its expression is associated with increased plasma LDL-C levels [19••] . The findings suggest enhancing expression of SORT1 could serve as a potential therapeutic strategy for hypercholesterolemia. In contrast, however, another study reported an opposite effect upon over-expression of Sort1, which was associated with increased hepatic release of lipoproteins and plasma LDL level [20••] . The contrasting results of these two studies hint to the complexity of identifying the molecular mechanisms in the model organisms to link the GWAS findings to the pathogenesis of atherosclerosis in humans.
Unaccounted Genetic Etiologies of Coronary Atherosclerosis ("Missing Heritability")
The findings of the GWAS do not seem to resolve the enigma of the genetic etiology of coronary atherosclerosis. The common alleles, as tested in the GWAS, account for a small fraction of heritability of complex phenotypes including coronary atherosclerosis. The tagger SNPs, which represent the common haplotypes, might not adequately cover the uncommon (MAF of 0.01 to 0.05) or rare (< 0.01) variants, which might predispose to atherosclerosis. The unaccounted genetic determinants of coronary atherosclerosis along with technological advances in the whole genome and whole exomesequencing approaches have raised considerable interest in testing the rare variant-common disease (RV-CD) hypothesis, which posits that multiple uncommon and rare susceptibility alleles are in part responsible for susceptibility for complex phenotypes. In accord with the large effect size of the causal rare variants in single gene disorders, it is generally expected that the uncommon and rare variants to exert larger effects on complex phenotypes than the common alleles. However, the RV-CD is largely an empiric question that remains to be tested through large-scale sequencing in carefully selected study populations (reviewed in [21] ). The "missing heritability", however, might have several other components, in addition to yet-to-be identified common and rare alleles. It might reflect in part an over-estimation of the heritable component of etiology of coronary atherosclerosis, genotype-genotype interactions (epistasis), and heritable epigenetic factors including microRNAs (reviewed in [22] ). Thus, finding the "missing heritability" of complex phenotypes, such as atherosclerosis might require discovering all DSVs in the genome, whether common or rare; discovering epigenetic determinants and deciphering the intertwined, often non-linear and stochastic interactions among the constituents that contribute to the pathogenesis of atherosclerosis.
Conclusions
Genotyping of over 230,000 cases with "coronary heart disease" and near 300,000 control individuals for >500,000 common SNPs over the past 7 years has led to identification of over 100 susceptibility loci for coronary atherosclerosis. The vast majority of the loci identified through GWAS encompass genes not previously implicated in the pathogenesis of atherosclerosis. Despite the enthusiasm for the discoveries, it remains to be seen whether and how soon the findings of GWAS will lead to discovering novel pathways in the pathogenesis of atherosclerosis and hence, new preventive and therapeutic targets. The clinical impact of mechanistic discoveries would likely be independent of the effect sizes of the susceptibility alleles detected in GWAS on atherosclerosis. Although the latter is modest and clinically negligible, the former could be as formidable as the effects of statins. Notwithstanding the significance of the mechanistic discoveries, the enigma of genetic etiologies of coronary atherosclerosis is expected to remain unexplained in the foreseeable future.
